

**Dr. Frank Jaschinski**

CSO Secarna Pharmaceuticals GmbH & Co. KG, Martinsried

**Therapeutic Antisense
Oligonucleotides: A Maturing
Technology Expanding the Universe of
Targetable Drug Targets**

Secarna Pharmaceuticals is a biopharmaceutical company redefining the discovery and development of best-in-class oligonucleotide therapeutics addressing disease indications with high unmet medical need. Secarna's mission is to maximize the performance and output of OligoCreator, its proprietary oligonucleotide discovery and development platform, to generate highly specific, safe, and efficacious best-in-class therapeutics. With over 20 discovery and development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where oligonucleotide-based approaches have clear potential benefits over other therapeutic modalities

Time: Monday, February 2, 2025; **13:00h**
Location: Seminarraum Physiologie
VKL 4.1.29
Universität Regensburg
and Zoom

To get the Zoom link please contact:
michaela.kritzenberger@ur.de